Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$850K
Filings
39
Firms Hired
3
Active Period
2021–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: MARSHALL & POPP, LLC
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R.2617
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: MARSHALL & POPP, LLC
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R.2617
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: MARSHALL & POPP, LLC
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R.2617
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: MARSHALL & POPP, LLC
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R.2617
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · fourth_quarter · Firm: MARSHALL & POPP, LLC
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R.6833
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · fourth_quarter · Firm: MARSHALL & POPP, LLC
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R.6833
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · fourth_quarter · Firm: MARSHALL & POPP, LLC
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R.6833
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · fourth_quarter · Firm: MARSHALL & POPP, LLC
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $60,000
Matched citations: H.R.6833
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $60,000
Matched citations: S.3799
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $60,000
Matched citations: S.3799
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $60,000
Matched citations: S.3799
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $60,000
Matched citations: S.3799
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $60,000
Matched citations: S.4348
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $60,000
Matched citations: S.4348
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $60,000
Matched citations: S.4348
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act, and H.R.2617, Consolidated Appropriations Act, 2023. Issues related to FDA regulation of medical devices, including including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, H.R.6833, Making continuing appropriations for fiscal year 2023, and H.R.2617, Consolidated Appropriations Act, 2023.
Client expense: — · Firm income: $60,000
Matched citations: S.4348
Handheld ultrasound and medical imaging issues, generally; no specific legislation S. 3799 Prevent PANDEMICS Act
Client expense: $110,000 · Firm income: —
Matched citations: S. 3799
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · third_quarter · Firm: MARSHALL & POPP, LLC
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act. Issues related to FDA regulation of medical devices, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R. 6833, making continuing appropriations for fiscal year 2023.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6833
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · third_quarter · Firm: MARSHALL & POPP, LLC
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act. Issues related to FDA regulation of medical devices, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R. 6833, making continuing appropriations for fiscal year 2023.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6833
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · third_quarter · Firm: MARSHALL & POPP, LLC
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act. Issues related to FDA regulation of medical devices, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R. 6833, making continuing appropriations for fiscal year 2023.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6833
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · third_quarter · Firm: MARSHALL & POPP, LLC
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act. Issues related to FDA regulation of medical devices, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R. 6833, making continuing appropriations for fiscal year 2023.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6833
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act. Issues related to FDA regulation of medical devices, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R. 6833, making continuing appropriations for fiscal year 2023.
Client expense: — · Firm income: $30,000
Matched citations: S.3799
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act. Issues related to FDA regulation of medical devices, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R. 6833, making continuing appropriations for fiscal year 2023.
Client expense: — · Firm income: $30,000
Matched citations: S.3799
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act. Issues related to FDA regulation of medical devices, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R. 6833, making continuing appropriations for fiscal year 2023.
Client expense: — · Firm income: $30,000
Matched citations: S.3799
Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act. Issues related to FDA regulation of medical devices, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R. 6833, making continuing appropriations for fiscal year 2023.
Client expense: — · Firm income: $30,000
Matched citations: S.3799
Source: Senate LDA